Labor Margin PressureDEMO
71
Tightening▲ +0.9
ValixData derived signalBLS · BEA · Census · public health data
OPEN → KNOWwhat changed · what matters · what is unusual · what comes next · evidencePrepared for this professional role
TODAY · 3-MINUTE OVERVIEWPharma / Biotech · daily overview
PREPARED AUTOMATICALLY FOR YOUR ROLE
COMPLEMENTS YOUR EXISTING SYSTEMS · DEMO SIGNAL VALUES
Since prior review3 material changesDemo count · Nova ranks the changes that deserve attention
Highest exceptionLabor Margin PressureTightening · source/freshness attached when live
Cross-signal readDemand / CapacityCompared with Reimbursement Context · relationship layer
Next catalysts4 monitoredDemo count · releases and events will populate here
Source readinessNews live · signals stagedOfficial connectors replace demo values without changing the workflow
TODAY'S REVIEW LIST
Labor Margin Pressure
Demand / Capacity
Capital Access
changes · exceptions · upcoming events · news · sourcesV
Current summary
How this works: advanced features appear only when the required data, history, access level, or connection is available
SINCE LAST REVIEWEstablishing local review baseline…Saved on this device onlyFinding the most important visible indicators…Brief 0
VALIXDATA · PHARMA / BIOTECH INTELLIGENCE NOW
What changed. What is unusual. What deserves attention.
DESK ENGINEREADYLive news + demo signals
ROLE-SPECIFIC SIGNAL MATRIX6 derived indicators configured
Demand / CapacityDEMO
71
Strengthening→ -0.2
ValixData derived signalBLS · BEA · Census · public health data
Reimbursement ContextDEMO
79
Tightening▲ +2.5
ValixData derived signalBLS · BEA · Census · public health data
Capital AccessDEMO
78
Watch▼ -1.0
ValixData derived signalBLS · BEA · Census · public health data
Utilization MomentumDEMO
74
Improving▲ +1.1
ValixData derived signalBLS · BEA · Census · public health data
Policy / Event VelocityDEMO
56
Stable→ -0.3
ValixData derived signalBLS · BEA · Census · public health data
CHANGE MAPSignal direction at a glance
DEMOLabor Margin PressureTightening
Demand / CapacityStrengthening
Reimbursement ContextTightening
Capital AccessWatch
Utilization MomentumImproving
Policy / Event VelocityStable
NOVA · PRIORITY INDUSTRY NEWSWhat this desk should see first
CONNECTINGConnecting the approved 24-hour Pharma / Biotech news feed…
Priority stories will replace this preview automatically.
No per-user AI call is required for the shared desk feed.
LIVE WHEN CONNECTED
Every calculated indicator will show its source, update time, methodology, and whether the value is live, reference, or demo. Temporary values are intentionally marked DEMO.
Open full Nova brief + news →Desk KPIs
#1
IRA Drug Pricing Impact
10 drugs (2026)
MANUAL
Number of drugs subject to Medicare price negotiation in first round. Negotiated prices take effect 2026. Revenue impact for named drugs is already flowing into consensus.
#2
FDA NDA/BLA Approvals (YTD)
14 NMEs
MANUAL
New molecular entity approvals year to date. Pace vs. prior years signals FDA productivity. Good for pipeline companies and bad for generics.
#3
Pharma M&A (YTD $B)
$74B
MANUAL
Year-to-date pharma/biotech M&A volume. Big pharma patent cliff driving acquisition urgency. High pace = premium valuations for clinical-stage targets.
#4
XBI Biotech Index (YTD)
-4.2%
MANUAL
Small/mid-cap biotech index performance. Underperformance vs. XPH signals risk-off for early-stage pipeline. Affects IPO and SPAC exit windows.
#5
PDUFA Dates (Next 30D)
6 upcoming
MANUAL
FDA prescription drug user fee act action dates in the next 30 days. Each date is a binary catalyst. Know which ones affect your coverage.
#6
Patent Cliff Exposure
$42B thru 2028
MANUAL
Combined revenue at risk from patent expirations at top 10 pharma companies through 2028. Drives acquisition urgency and pipeline licensing activity.
#7
Biosimilar Market Share
22% of biologic$
MANUAL
Biosimilar penetration of originator biologics. Rising = reference product revenue declining faster than models project. Impact on Humira, Keytruda successors.
#8
Phase III Success Rate
51%
MANUAL
Industry average Phase III clinical trial success rate. The denominator of every pipeline valuation. By disease area varies significantly — oncology lower.
Data notes & methodology
About these tiles — the eight values above are reference baselines for the pharma / biotech seat, drawn from FRED, EIA, BLS, and curated industry sources. The live crypto and FX panels below refresh from public APIs every 60 seconds; KPI values would refresh from their cited sources via a backend proxy in the production deployment.
Aria Intelligence Brief
● Live
Pharma / Biotech read & analyst summary
Ask Aria for the current read once the relevant desk data has loaded.
Aria explains the indicators, changes, current news and source context shown on this desk,
while keeping the professional responsible for the decision.
Aria explains the indicators, changes, current news and source context shown on this desk,
while keeping the professional responsible for the decision.
Additional market contextOptional · loads only when opened
Top-20 Cap
—
24h Volume
—
BTC Dominance
—
Market Breadth
—
Digital asset market context
| # | Asset | Price | 24h | 7d | Mkt Cap | 7d Trend |
|---|---|---|---|---|---|---|
| Fetching live quotes… | ||||||
FX market context
About this desk
Key indicators, overnight industry intelligence, source provenance, and desk-aware analysis in one persistent workspace.
Key indicatorsConfigured · sources shown
Industry newsLive 24h desk feed
AriaExplains this desk's data
NovaAutomatic overnight brief
The ValixData Pharma / Biotech desk organizes market context for professionals working in healthcare. It separates live market feeds from reference indicators so readers can see what is current, what is a baseline, and which source supports each figure.
The desk focuses on signals including IRA Drug Pricing Impact, FDA NDA/BLA Approvals (YTD), Pharma M&A (YTD $B), XBI Biotech Index (YTD), and related indicators.
Desk status: Core desk. Reference values are not presented as live production feeds. Source cadence and methodology are documented on the methodology page.
Read data methodology →Pharma / Biotech is a Core desk.
Core means the profession has an explicit signal configuration. Commercial priority is driven by demand, source readiness and economics.
How paid desks are selected →